Premium
Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy
Author(s) -
Strender LarsErik,
Blomgren Henric,
Petrini Björn,
Wasserman Jerzy,
Forsgren Marianne,
Norberg Renée,
Baral Edward,
Wallgren Arne
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19811101)48:9<1996::aid-cncr2820480915>3.0.co;2-m
Subject(s) - medicine , chemotherapy , chlorambucil , methotrexate , antibody , breast cancer , adjuvant , immunology , gastroenterology , cytomegalovirus , lymphocyte , cancer , cyclophosphamide , virus , herpesviridae , viral disease
A group of 17 patients, having undergone modified radical mastectomy for breast cancer, received 12 cycles of chemotheray with methotrexate, 5‐fluorouracil, and chlorambucil during 17 months. The number of circulating T and non T lymphocytes, as defined by E, EAC, and ME rosette formation, were reduced during treatment. The Non‐T lymphocytes, however, were reduced to the highest relative extent. Relative phytohemagglutinin and mixed lymphocyte culture responses of the cells decreased, whereas purified protein derivative responses were unchanged. Serum concentrations of IgM were reduced, but IgA and IgG concentrations were unchanged or slightly increased. Antibody titres to morbilli and herpes simplex were not changed, whereas the antibody activity against cytomegalovirus (CMV) increased in several seropositive patients. None of these patients, however, developed signs of a CMV infection.